title: Effects of oral administration of benzylamine on glucose tolerance and lipid metabolism in rats.
abstract: Repeated administration of benzylamine plus vanadate have been reported to exhibit anti-hyperglycemic effects in different models of diabetic rats. Likewise oral treatment with Moringa oleifera extracts which contain the alkaloïd moringine, identical to benzylamine, has also been shown to prevent hyperglycemia in alloxan-induced diabetic rats. With these observations we tested whether prolonged oral administration of benzylamine could interact with glucose and/or lipid metabolism. Seven week old male Wistar rats were treated for seven weeks with benzylamine 2.9 g/l in drinking water and were submitted to glucose tolerance tests. A slight decrease in water consumption was observed in benzylamine-treated animals while there was no change in body and adipose tissue weights at the end of treatment. Blood glucose and plasma insulin, triacylglycerol or cholesterol levels were not modified. However, benzylamine treatment resulted in a decrease in plasma free fatty acids in both fed and fasted conditions. Benzylamine treatment improved glucose tolerance as shown by the reduction of hyperglycemic response to intra-peritoneal glucose load. Oral benzylamine treatment did not alter the response of adipocytes to insulin nor to insulin-like actions of benzylamine plus vanadate, via in vitro activation of glucose transport or inhibition of lipolysis. This work demonstrates for the first time that oral administration of benzylamine alone influences glucose and lipid metabolism. However, these results obtained in normoglycemic rats require to be confirmed in diabetic models.
authors.affiliation: INSERM U586, IFR 31, Bat L3, CHU Rangueil, 31432 Toulouse cedex 9, France.
authors.forename: S
authors.initials: S
authors.lastname: Bour
authors.forename: V
authors.initials: V
authors.lastname: Visentin
authors.forename: D
authors.initials: D
authors.lastname: Prévot
authors.forename: D
authors.initials: D
authors.lastname: Daviaud
authors.forename: J S
authors.initials: JS
authors.lastname: Saulnier-Blache
authors.forename: C
authors.initials: C
authors.lastname: Guigne
authors.forename: P
authors.initials: P
authors.lastname: Valet
authors.forename: C
authors.initials: C
authors.lastname: Carpéné
mesh_terms: D017667:Adipocytes / Q000378:metabolism; D000284:Administration, Oral; D000818:Animals; D001596:Benzylamines / Q000008:administration & dosage* / Q000494:pharmacology*; D001786:Blood Glucose / Q000378:metabolism; D002784:Cholesterol / Q000097:blood; D004435:Eating; D005230:Fatty Acids, Nonesterified / Q000097:blood; D005947:Glucose / Q000378:metabolism*; D005951:Glucose Tolerance Test; D007328:Insulin / Q000097:blood; D050356:Lipid Metabolism; D008066:Lipolysis; D008297:Male; D051381:Rats; D017208:Rats, Wistar; D013997:Time Factors; D014280:Triglycerides / Q000097:blood
chemical_list: D001596:Benzylamines; D001786:Blood Glucose; D005230:Fatty Acids, Nonesterified; D007328:Insulin; D014280:Triglycerides; D002784:Cholesterol; C030796:benzylamine; D005947:Glucose